Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) Short Interest Up 1,280,070.0% in June

Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 2,560,340 shares, an increase of 1,280,070.0% from the May 31st total of 200 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Shanghai Junshi Biosciences Stock Performance

Shares of Shanghai Junshi Biosciences stock remained flat at C$3.35 during trading on Thursday. Shanghai Junshi Biosciences has a 52-week low of C$2.99 and a 52-week high of C$4.23. The company’s 50-day moving average is C$3.23 and its 200-day moving average is C$3.14.

Shanghai Junshi Biosciences Company Profile

Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.

Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.